Browse
Submit Data
Databases
API
Help

Dataset Information

8 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Best timing of EGFR re-challenge by monitoring the mutant allele of KRAS/NRAS in liquid biopsy

ABSTRACT: Primary outcome(s): The dynamics of the positive RAS mutations rate by circulating tumor DNA analysis using OncoBEAM RAS CRC KIT

DISEASE(S): Patients With Ras/braf V600e Wild-type Unresectable Advanced Or Recurrent Colorectal Cancer Who Have Been Treated With Anti-egfr Monoclonal Antibody

PROVIDER: 2651470 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Panitumumab re-challenge strategy for liquid RAS mutation negative metastatic colorectal cancer

Project description:Interventions: Panitumumab 6 mg / kg and irinotecan 150 mg / m 2 are administered once every two weeks (14 days) until it meets protocol termination criteria. Primary outcome(s): Objective response rate:ORR (Investigator’s judgment based on RECIST guideline ver. 1.1) Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

| 2614266 | ecrin-mdr-crc

Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring.

Project description: Not available

| S-EPMC8468624 | biostudies-literature

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

Project description:The purpose of SIBYL is to generate clinical validity data for the ability of a future version of Guardant360 developed by Guardant Health to measure response to systemic therapy in patients with unresectable advanced solid tumors. It is necessary to collect clinical data points and treatment outcomes in order to demonstrate clinical validity for longitudinal monitoring with ctDNA and correlation of ctDNA dynamics with therapeutic response, as evaluated by standard methods, including RECIST 1.1 and CT scan measurements.

| 65750 | ecrin-mdr-crc

Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal Cancer.

Project description: Not available

| S-EPMC5789760 | biostudies-literature

Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer.

Project description: Not available

| S-EPMC8170728 | biostudies-literature

Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma.

Project description: Not available

| S-EPMC7397208 | biostudies-literature

Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR

Project description:patients with metastatic colorectal cancer who were initially RAS wild and failed at least 2 lines of chemotherapy will be enrolled. Anti-EGFR must have been given in 1st line. Those who remain RAS-wild upon retesting will receive rechallenge with panitumumab and chemotherapy

| 2304800 | ecrin-mdr-crc

Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC

Project description:The aim of the trial is to study the efficacy and safety of Cetuximab re-challenge for Chinese Patients with RAS/BRAF wild-type Metastatic Colorectal Cancer.

| 2326638 | ecrin-mdr-crc

Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring.

Project description: Not available

| S-EPMC6163729 | biostudies-literature

Thermal liquid biopsy for monitoring melanoma patients under surveillance during treatment: A pilot study.

Project description: Not available

| S-EPMC6483604 | biostudies-literature